Evidence map›Paper›PMID 39535577›Full record

ReviewAmerican journal of clinical dermatology2025

Managing Urticarial Vasculitis: A Clinical Decision-Making Algorithm Based on Expert Consensus.

Nikolai Dario Rothermel, Carolina Vera Ayala, Margarida Gonçalo, Jie Shen Fok, Leonie Shirin Herzog, Emek Kocatürk, Sophia Neisinger, Manuel P Pereira, Indrashis Podder, Polina Pyatilova and 6 more

Abstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of clinical dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nikolai Dario RothermelInstitute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 27, 12203, Berlin, Germany.
Carolina Vera AyalaInstitute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 27, 12203, Berlin, Germany.ORCID http://orcid.org/0000-0002-7963-5935
Margarida GonçaloDermatology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.ORCID http://orcid.org/0000-0001-6842-1360
Jie Shen FokDepartment of Respiratory Medicine and General Medicine, Box Hill Hospital, Eastern Health, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-3450-0877
Leonie Shirin HerzogInstitute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 27, 12203, Berlin, Germany.ORCID http://orcid.org/0000-0002-7691-0372
Emek KocatürkInstitute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 27, 12203, Berlin, Germany.ORCID http://orcid.org/0000-0003-2801-0959
Sophia NeisingerInstitute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 27, 12203, Berlin, Germany.ORCID http://orcid.org/0009-0000-5967-4809
Manuel P PereiraInstitute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 27, 12203, Berlin, Germany.ORCID http://orcid.org/0000-0001-5649-2698
Indrashis PodderDepartment of Dermatology, College of Medicine, Sagore Dutta Hospital, Kolkata, India.ORCID http://orcid.org/0000-0002-9589-083X
Polina PyatilovaInstitute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 27, 12203, Berlin, Germany.ORCID http://orcid.org/0000-0001-5520-2900
Aiste RamanauskaiteInstitute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 27, 12203, Berlin, Germany.ORCID http://orcid.org/0009-0004-9289-5960
Melba MunozInstitute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 27, 12203, Berlin, Germany.ORCID http://orcid.org/0000-0003-3386-4502
Karoline KrauseInstitute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 27, 12203, Berlin, Germany.ORCID http://orcid.org/0000-0001-9711-9654
Marcus MaurerInstitute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 27, 12203, Berlin, Germany.ORCID http://orcid.org/0000-0002-4121-481X
Hanna Bonnekoh *Institute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 27, 12203, Berlin, Germany.ORCID http://orcid.org/0000-0002-3567-0149
Pavel Kolkhir *Institute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 27, 12203, Berlin, Germany. pavel.kolkhir@charite.de.ORCID http://orcid.org/0000-0001-5380-8132

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urticarial vasculitis (UV) is a rare and difficult-to-treat, small-vessel leukocytoclastic vasculitis presenting with recurrent long-lasting wheals. So far, no guidelines and treatment algorithms exist that could help clinicians with the management of UV. In this review, we describe evidence on systemic treatments used for UV and propose a clinical decision-making algorithm for UV management based on the Urticarial Vasculitis Activity Score assessed for 7 days (UVAS7). Patients with occasional UV-like urticarial lesions and patients with UV with skin-limited manifestations and/or mild arthralgia/malaise (total UVAS7 ≤7 of 70) can be initially treated using the step-wise algorithm for chronic urticaria including second-generation H1-antihistamines, omalizumab, and cyclosporine A. Patients with UV with more severe symptoms (UVAS7 >7), especially those with hypocomplementemic UV, may require a multidisciplinary approach, particularly if underlying diseases, for example, systemic lupus erythematosus, cancer, or infection, are present. Immunomodulatory therapy is based on clinical signs and symptoms, and the drug availability and safety profile, and includes systemic corticosteroids, dapsone, hydroxychloroquine, anti-interleukin-1 agents, and other therapies. The level of evidence for all UV treatments is low. Prospective studies with current and novel drugs are needed and could provide further insights into UV pathogenesis and treatment.

Indexed as

AlgorithmsClinical Decision-MakingUrticariaVasculitis, Leukocytoclastic, CutaneousConsensusHumansPractice Guidelines as TopicSeverity of Illness Index

Identifiers

PMID39535577
PMCPMC11748462

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.